PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+18.47%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.84B
AUM Growth
+$2.84B
(+33%)
Cap. Flow
+$546M
Cap. Flow
% of AUM
19.24%
Top 10 Holdings %
Top 10 Hldgs %
58.91%
Holding
39
New
10
Increased
16
Reduced
5
Closed
5
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$140M |
| 2 |
Revolution Medicines
RVMD
|
$93.9M |
| 3 |
Vaxcyte
PCVX
|
$84.7M |
| 4 |
Arvinas
ARVN
|
$69.5M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$66.8M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $314M | 11.04% | 4,177,830 +319,822 | +8% | +$24M |
|
2
Arcellx
ACLX
$3.85B
| $266M | 9.35% | 3,818,095 +159,471 | +4% | +$11.1M |
|
3
argenx
ARGX
$43.6B
| $217M | 7.65% | 552,120 +129,543 | +31% | +$51M |
|
4
Disc Medicine
IRON
$2.07B
| $149M | 5.24% | 2,389,902 +4,045 | +0.2% | +$252K |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $146M | 5.15% | 3,124,749 +811,830 | +35% | +$38M |
|
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $140M | 4.91% | +1,078,346 | New | +$140M |
|
7
Immunocore
IMCR
$1.62B
| $116M | 4.09% | 1,787,176 +333,293 | +23% | +$21.7M |
|
8
Legend Biotech
LEGN
$6.41B
| $111M | 3.91% | 1,982,006 +87,362 | +5% | +$4.9M |
|
|
9
Arvinas
ARVN
$568M
| $108M | 3.8% | 2,614,935 +1,683,632 | +181% | +$69.5M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $107M | 3.77% | 2,484,874 +357,474 | +17% | +$15.4M |
|
|
11
Tarsus Pharmaceuticals
TARS
$2.47B
| $104M | 3.66% | 2,863,406 +1,838,406 | +179% | +$66.8M |
|
|
CERE
12
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $98.5M | 3.47% | 2,330,508 | – | – |
|
|
13
Revolution Medicines
RVMD
$7.1B
| $93.9M | 3.31% | +2,914,975 | New | +$93.9M |
|
14
Olema Pharmaceuticals
OLMA
$375M
| $89.5M | 3.15% | 7,903,600 | – | – |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $88.1M | 3.1% | 5,031,420 +236,932 | +5% | +$4.15M |
|
|
16
Vaxcyte
PCVX
$4B
| $84.7M | 2.98% | +1,239,995 | New | +$84.7M |
|
|
ALPN
17
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $84.1M | 2.96% | 2,121,163 -1,055,580 | -33% | -$41.8M |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$511M
| $80.8M | 2.85% | 3,246,759 -460,242 | -12% | -$11.5M |
|
19
Ascendis Pharma
ASND
$11.8B
| $76.8M | 2.7% | 507,952 +156,252 | +44% | +$23.6M |
|
20
Kura Oncology
KURA
$686M
| $66.9M | 2.35% | 3,135,387 +1,872,559 | +148% | +$39.9M |
|
21
Edgewise Therapeutics
EWTX
$1.51B
| $44.6M | 1.57% | +2,446,373 | New | +$44.6M |
|
|
AUTL
22
Autolus Therapeutics
AUTL
$399M
| $41M | 1.44% | 6,425,803 -6,185,532 | -49% | -$39.5M |
|
23
Y-mAbs Therapeutics
YMAB
$388M
| $36.3M | 1.28% | +2,233,610 | New | +$36.3M |
|
24
Immatics
IMTX
$619M
| $29.6M | 1.04% | 2,818,908 +682,569 | +32% | +$7.17M |
|
25
Immunovant
IMVT
$2.56B
| $25.8M | 0.91% | +799,054 | New | +$25.8M |
|